{"id":"ak112-with-scrt-and-capeox","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AK112 functions as a dual checkpoint inhibitor by binding both PD-1 and LAG-3 on T cells, relieving immune suppression and promoting T-cell activation and proliferation. When combined with CapeOX chemotherapy, the regimen aims to synergistically enhance anti-tumor immunity through both checkpoint blockade and direct cytotoxic effects on cancer cells.","oneSentence":"AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, combined with chemotherapy (capecitabine and oxaliplatin) to treat solid tumors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:21:21.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with capecitabine and oxaliplatin)"}]},"trialDetails":[{"nctId":"NCT06718543","phase":"PHASE2","title":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"fan li","startDate":"2025-02-10","conditions":"Rectal Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["short-course radiotherapy","CapeOX"],"phase":"phase_2","status":"active","brandName":"AK112 with SCRT and CapeOX","genericName":"AK112 with SCRT and CapeOX","companyName":"fan li","companyId":"fan-li","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, combined with chemotherapy (capecitabine and oxaliplatin) to treat solid tumors. Used for Advanced or metastatic solid tumors (in combination with capecitabine and oxaliplatin).","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}